#LCSM Chat 2019/01/06–Immunotherapy: What Patients Need To Know
It’s a new year, and #LCSM Chat is transitioning to monthly chats. Our first chat is a collaborative chat across all cancer hashtag communities titled “Immunotherapy: What Patients Need to Know.” The discussion will cover all types of immunotherapy currently approved for treatment of any cancer. Chat moderator Janet Freeman-Daily (@JFreemanDaily) will be joined by special guest Lisa Rezende (@LisaRezende1), a biology educator (Assistant Professor of Practice) on the Molecular and Cellular Biology faculty at the University of Arizona. Lisa is also a long-term volunteer cancer advocate with FORCE (Facing Our Risk of… Read More
#LCSM Chat topic 11/17– FB Live Q&A with NCI on Immunotherapy and Clinical Trials
For Lung Cancer Awareness Month, the National Cancer Institute (NCI) is once again partnering with #LCSM Chat for a special event. During the first half of our November 17 tweetchat, which starts at the usual 8 PM Eastern time (5 PM Pacific), the NCI’s Dr. Shakun Malik (head of thoracic oncology therapeutics) and Janet Freeman-Daily (lung cancer patient/activist and founding member of #LCSM Chat) will have a 30-minute Facebook Live question and answer session on the topic of “Immunotherapy for Lung Cancer: New Research and Clinical Trials.” The Facebook Live event will… Read More
#LCSM Chat Topic 3/26: The Landscape of the #LungCancer World After Opdivo–Where We Are, Where We’re Going
Post by #LCSM Moderator Dr. H. Jack West: Earlier this month, the FDA made quick work of the application that Bristol-Myers-Squibb had just completed for Opdivo (nivolumab) for patients with squamous cell NSCLC that has previously been treated with standard chemotherapy. This was a very rapid decision, which highlighted the improvement in median overall survival from 6 to 9.2 months. So where are we now? What are the implications of the approval, both in terms of future approvals and the current treatment options for patients? Will Opdivo be the default best treatment… Read More
You must be logged in to post a comment.